COVID-19 Vaccine Information for Gaucher Patients

As of 3/18/2021. All information contained is provided with input from physicians on the NGF Medical Advisory Board.

Please remember that this website provides only general information about COVID-19. Your Gaucher specialist is the best person to advise you about your health.

Medical understanding of COVID-19 is evolving. To maintain your optimal health, follow your local guidance and CDC COVID-19 recommendations.

COVID-19 and Gaucher

You should continue all treatments and medical management of lysosomal disorders, including Gaucher disease. Before making any changes to your medical regimen, or if you need care for COVID-19-related illness, seek advice from both your Gaucher specialist and your primary care provider (PCP). Learn more about coronavirus and people with Gaucher disease.

COVID-19 Vaccines Available Now

The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to make three vaccines available in the United States. These vaccines are:

  • Pfizer-BioNTech: This mRNA vaccine requires two doses, 21 days apart.
  • Moderna: Another mRNA vaccine, this vaccine requires two doses, 28 days apart.
  • Janssen-Johnson & Johnson: This recombinant adenovirus vaccine requires only one injection.

Each state has its own vaccination schedule and regulations. Look to local authorities to determine when you may be eligible to receive the vaccine. For vaccines that require two doses, administering the second dose up to 42 days after the initial dose has been shown to be effective.

Who Can Receive a COVID-19 Vaccine?

CDC’s Interim Clinical Considerations indicate that the vaccines may be administered to persons with underlying medical conditions who have no contraindications to vaccination.

Answers to Other Questions About COVID-19 Vaccines and Gaucher

As more people become vaccinated and the COVID-19 pandemic continues to evolve, we will update this section. Meanwhile, here is what we know:

The COVID vaccine offers several major benefits. The vaccine:

  • Significantly lowers the likelihood of getting COVID-19.
  • Reduces the severity of the disease if contracted.
  • Protects others around you by reducing prevalence of the SARS-CoV-2 virus among the general population.

Vaccination is an important tool to help society return to normal. All vaccines have gone through a rigorous approval process.

Careful trials of the vaccines indicate that they are safe and effective at preventing COVID-19 infection and preventing serious illness even if you get COVID-19. 

Currently, COVID-19 vaccines have an Emergency Use Authorization (EUA) for people age 16 or older (Pfizer) or 18 and older (Moderna and Johnson & Johnson).

We do not know whether these vaccines will be as effective in GD patients as in everyone else, but there is no evidence to the contrary. To the best of our collective knowledge, there is no reason why patients with Gaucher disease would have additional adverse events from the vaccines. Therefore, vaccination is recommended for patients with Gaucher disease, unless advised otherwise by physicians.

If you already had COVID-19, you can still get the vaccine. Check for the latest recommendations from the CDC and discuss with your physicians.

COVID-19 can be a serious, highly infectious and unpredictable illness. The risks of COVID infection far outweigh the risks associated with the vaccine. The disease is still spreading rapidly through communities in the United States and elsewhere.

Like most vaccines, the shot can cause mild side effects. These reactions go away after a few days. Vaccine side effects may include:

  • Swelling, redness and pain of the injected  arm
  • Fatigue, sometimes severe
  • Muscle and joint pain
  • Fever

Very rarely, predisposed allergic individuals could have an anaphylactic reaction. All individuals receiving vaccines are monitored for at least 15 minutes post-injection to reasonably assure no anaphylaxis.

Additional and serious side effects are extremely rare in our relatively short-term post-vaccination .

As recommended for anyone receiving such vaccinations, persons with Gaucher disease who have previously had a major allergic reaction (anaphylaxis) to food, or to Gaucher or other medications should alert the healthcare facility providing the injection and should be closely monitored for at least 30 minutes after their injection.

If you receive Enzyme Replacement Therapy (ERT), we suggest that you do not get vaccinated on an infusion day.

Recent studies from Israel suggest that ~2 in 10,000 people who have been vaccinated have had symptomatic COVID-19. In people who have received the vaccine and contracted COVID, the illness remains mild and, except in very rare cases, requires no specialized care.

It is still unknown if and how many individuals can have asymptomatic infection after vaccination and, therefore, transmit the disease to others. It is important to continue to follow CDC mitigation guidelines after vaccination. 

We do not yet know how long immunity to COVID-19 disease will last after infection or immunization. We also do not have information about how variable that immunity will be among individuals with or without GD. Therefore, it is still unknown if and how often booster vaccination may be necessary.

CDC guidelines and recommendations change to reflect the current understanding of COVID-19. Stay informed with the most current information.

The vaccines teach your body to recognize the COVID-19 virus and mount its own defense to the virus. They work as follows:

  • mRNA vaccines: Messenger RNA tells the body to make the spike protein found on the outside of the virus. Then the body’s own cells react to that protein. The vaccine trains your own immune cells to fight back any further infection. The mRNA rapidly deteriorates, and your body disposes it as waste. The mRNA does not enter your cells’ nucleus and cannot change the makeup of your cells.
  • Modified adenovirus vaccine: The vaccine uses a deactivated cold virus changed to include the spike protein on the outside of the SARS-CoV-2 virus. The modified virus can’t reproduce in your body. The vaccine travels to your cells, which “read” the protein and start making antibodies to the virus.



The SARS-CoV-2 virus, like other viruses, is mutating (changing) as it spreads in the human population worldwide. New variants have emerged from the United Kingdom, South Africa, Brazil, and Finland.

The effectiveness of the current vaccines against these new mutant strains is still unknown. Some variants may have some ability to get around the body’s immune response. We expect that in the future, vaccine manufacturers will work to develop updated versions of the vaccine.

Meanwhile, vaccination, following the CDC guidelines, is still recommend to provide significant protection against the SARS-CoV-2 virus.

No. None of the vaccines can cause a COVID-19 infection. The vaccine does not inject the virus into people.

The vaccines currently available have only been approved for those over age 16 (Pfizer) or over 18 (Moderna and Johnson & Johnson). Clinical trials underway in children, and approval is likely in the coming months.

Each state decides how they will distribute the vaccine. The official recommendations state that people over age 65 and those who have underlying health risks should get priority over the general population.

In our view, Gaucher disease is a chronic medical disorder, and thus our patients are considered to have an underlying health problem.

That being said, our collective experience over the past months indicate that patients with Gaucher disease who do not have other serious health issues do not seem to be more susceptible to COVID-19, nor do they appear to have more severe cases just because of Gaucher disease.

The Israel Institute for Biological Research shared news releases about a pre-peer-reviewed paper on the possible use of Gaucher medications to treat and/or prevent COVID-19 viral illness. The medications are analogues of eliglustat (Cerdelga®) and venglustat, a third-generation substrate inhibitor currently in clinical trials for Gaucher disease types 1 and 3.

The NGF requested and received feedback from the Medical Advisory Board regarding the recent press releases. In essence:

  • There is no confirmed evidence that existing Gaucher medicines have an effect on COVID-19.
  • Gaucher patients should continue their current treatment unless otherwise directed by their Gaucher specialists.

Additional Coronavirus Resources for Gaucher Patients

Gaucher disease is one of many factors that uniquely affect your health. Seek advice from your Gaucher specialist as well as your PCP. Other resources that may interest you include:

Thank You to Our Advising Gaucher Specialists

A panel of Gaucher specialists from Gaucher treatment centers addressed the questions above regarding the new COVID-19 vaccines.

Information on this page was contributed by a panel of Gaucher specialists including: Manisha Balwani, MD; Deborah S. Barboth, MD; T. Andrew Burrow, MD; Robin Ely, MD; Edward I. Ginns, MD, PhD; Ozlem Goker-Alpan, MD; Gregory A. Grabowski, MD; Priya S. Kishnani, MD; Heather Lau, MD; Nicola Longo, MD, PhD; Grisel Lopez, MD; Gustavo Maegawa, MD, PhD; Pramod Mistry, MBBS, PhD; Seymour Packman, MD; Barry Rosenbloom, MD; Tamanna Roshan Lal, MB ChB; Raphael Schiffmann, MD; Ellen Sidransky, MD; and Neal Weinreb, MD.

Stay in Touch with NGF

Learn about the latest research, news and events.